Move follows expert concerns over potential misuse and intoxication; retailers will have to maintain detailed sales records for the four CNS medicines under Schedule H1
Read more at the source
Disclaimer: The content of this post is sourced from external sites and is for informational purposes only. All rights and credits belong to the original authors and publishers.